NCT05991388 2026-02-20
Glo-BNHL
University of Birmingham
Phase 2/3 Recruiting
Clinical Trials
7 trialsNCT05821088 2025-11-20
Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 2 Recruiting
NCT07081022 2025-08-21
JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma
Shanghai Junshi Bioscience Co., Ltd.
Phase 2 Recruiting
NCT02628405 2024-07-01
R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma
Academic and Community Cancer Research United
Phase 1/2 Active not recruiting
NCT00588094 2015-12-04
Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHL
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01300793 2012-09-26
V-RICE
University of California, San Francisco
Phase 1 Terminated
NCT00515138 2012-04-12
A Pilot Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide (RICE) Plus Bortezomib (Velcade) in a Dose-Escalating Fashion for Patients With Relapsed or Primary Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma Who Are Candidates for Autologous Stem Cell Transplant
University of California, San Francisco
Phase EARLY_PHASE1 Terminated